Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784704 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
A Phase 3 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT02784704 is a Phase 3 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 500 participants.
The verdict
NCT02784704, a Phase 3 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics (PK) of eravacycline compared with meropenem in the treatment of complicated intra-abdominal infections (cIAIs).
Interventions
- DRUG Placebo
- DRUG Eravacycline
- DRUG Meropenem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2016-10-13 |
| Est. Completion | 2017-05-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784704
The ClinicalTrials.gov registry entry for NCT02784704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02784704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784704 about?
NCT02784704 is a clinical study titled "Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections". This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics (PK) of eravacycline compared with meropenem in the treatment of complicated intra-abdominal infections (cIAIs).
What is the current status of trial NCT02784704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2016-10-13. Estimated completion is 2017-05-19.
What interventions are being tested in trial NCT02784704?
The interventions under investigation include: Placebo (DRUG), Eravacycline (DRUG), Meropenem (DRUG).
Who is sponsoring clinical trial NCT02784704?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.